Wei Xiong

6PUBLICATIONS

63CO-AUTHORS

Predictive and prognostic markersHaematological tumoursMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Pharmacogenomics

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (6)

Sort by Publication Date:

|Jun 03, 2026

Monoclonal antibodies targeting PCDH7 inhibit tumor growth and enhance immune responses in KRAS-mutant non-small cell lung cancer.

|Mar 27, 2025

Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development.

Yubo He, Chengcheng Zhang, Lingxiao Tan

|Mar 07, 2025

177Lu-Labeled Antibody-Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors.

Aiko Yamaguchi, Chisato M Yamazaki, Yasuaki Anami

|Dec 19, 2023

LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development.

Ryan Huang, Xiaoye Liu, Jaehyup Kim

|Nov 22, 2023

Hyperleptinemia contributes to antipsychotic drug-associated obesity and metabolic disorders.

Shangang Zhao, Qian Lin, Wei Xiong

|Jul 06, 2022

An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody-Drug Conjugates.

Summer Y Y Ha, Yasuaki Anami, Chisato M Yamazaki

Pageof 1

Frequent Collaborators

Ningyan Zhang

Zhiqiang An

Summer Y Y Ha

Yasuaki Anami

Chisato M Yamazaki

Hui Deng

Mi Deng

Xiaoye Liu

Kyoji Tsuchikama

Ryan Huang

Frequent Collaborators

Ningyan Zhang

Zhiqiang An

Summer Y Y Ha

Yasuaki Anami